| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
|
N Engl J Med
|
2005
|
15.30
|
|
2
|
MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA.
|
Mol Cell Biol
|
2008
|
4.45
|
|
3
|
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
|
Blood
|
2006
|
3.89
|
|
4
|
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
|
Clin Cancer Res
|
2008
|
3.50
|
|
5
|
Environment-mediated drug resistance: a major contributor to minimal residual disease.
|
Nat Rev Cancer
|
2009
|
3.49
|
|
6
|
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.
|
Blood
|
2003
|
2.41
|
|
7
|
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.
|
Blood
|
2010
|
2.37
|
|
8
|
Implementing personalized medicine in a cancer center.
|
Cancer J
|
2011
|
1.69
|
|
9
|
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.
|
Blood
|
2007
|
1.65
|
|
10
|
Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.
|
Cancer Res
|
2009
|
1.55
|
|
11
|
Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.
|
Oncogene
|
2003
|
1.52
|
|
12
|
Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
|
Cancer Res
|
2003
|
1.47
|
|
13
|
Proteomic contributions to personalized cancer care.
|
Mol Cell Proteomics
|
2008
|
1.46
|
|
14
|
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells.
|
Oncogene
|
2003
|
1.44
|
|
15
|
The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
|
Blood
|
2005
|
1.43
|
|
16
|
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
|
Oncogene
|
2002
|
1.38
|
|
17
|
ABCG2 expression, function, and promoter methylation in human multiple myeloma.
|
Blood
|
2006
|
1.27
|
|
18
|
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
|
Cancer Res
|
2009
|
1.25
|
|
19
|
A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer.
|
Proteomics Clin Appl
|
2011
|
1.25
|
|
20
|
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
|
Blood
|
2004
|
1.24
|
|
21
|
Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas.
|
Blood
|
2007
|
1.23
|
|
22
|
On the eve of personalized medicine in oncology.
|
Cancer Res
|
2008
|
1.21
|
|
23
|
Tumor microenvironment and drug resistance in hematologic malignancies.
|
Blood Rev
|
2006
|
1.16
|
|
24
|
A protective role for the human SMG-1 kinase against tumor necrosis factor-alpha-induced apoptosis.
|
J Biol Chem
|
2008
|
1.13
|
|
25
|
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
|
Cancer
|
2006
|
1.12
|
|
26
|
Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a.
|
Blood
|
2010
|
1.06
|
|
27
|
Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
|
Cancer Res
|
2006
|
1.05
|
|
28
|
Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines.
|
J Immunol
|
2002
|
1.04
|
|
29
|
Collaborative biomedicine in the age of big data: the case of cancer.
|
J Med Internet Res
|
2014
|
1.04
|
|
30
|
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
|
Clin Cancer Res
|
2006
|
1.02
|
|
31
|
HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells.
|
Mol Cancer Ther
|
2009
|
0.99
|
|
32
|
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
|
J Clin Invest
|
2013
|
0.99
|
|
33
|
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
|
Clin Cancer Res
|
2005
|
0.98
|
|
34
|
The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
|
Exp Cell Res
|
2004
|
0.97
|
|
35
|
Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone.
|
Mol Cancer Ther
|
2002
|
0.96
|
|
36
|
Kinome siRNA screen identifies SMG-1 as a negative regulator of hypoxia-inducible factor-1alpha in hypoxia.
|
J Biol Chem
|
2009
|
0.95
|
|
37
|
Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.
|
Mol Cancer Ther
|
2010
|
0.93
|
|
38
|
HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
|
Br J Haematol
|
2008
|
0.92
|
|
39
|
Environmental-mediated drug resistance: a target for multiple myeloma therapy.
|
Expert Rev Hematol
|
2009
|
0.92
|
|
40
|
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
|
Mol Cell Proteomics
|
2011
|
0.86
|
|
41
|
Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
|
Clin Cancer Res
|
2003
|
0.85
|
|
42
|
A novel TNF receptor-associated factor 6 binding domain mediates NF-kappa B signaling by the common cytokine receptor beta subunit.
|
J Immunol
|
2010
|
0.83
|
|
43
|
Discovery, Development, and clinical applications of bortezomib.
|
Oncology (Williston Park)
|
2004
|
0.83
|
|
44
|
AACR Cancer Progress Report 2012.
|
Clin Cancer Res
|
2012
|
0.82
|
|
45
|
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
|
Cancer Chemother Pharmacol
|
2003
|
0.79
|
|
46
|
Static adhesion of cancer cells to glass surfaces coated with glycosaminoglycans.
|
Colloids Surf B Biointerfaces
|
2008
|
0.79
|
|
47
|
Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery.
|
Mol Cancer Ther
|
2002
|
0.79
|
|
48
|
Turning the tide against cancer through sustained medical innovation: the pathway to progress.
|
Clin Cancer Res
|
2014
|
0.77
|
|
49
|
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
|
Am J Hematol
|
2014
|
0.76
|
|
50
|
An ET-CURE pilot project supporting undergraduate training in cancer research, emerging technology, and health disparities.
|
J Cancer Educ
|
2012
|
0.75
|
|
51
|
Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies.
|
Clin Cancer Res
|
2005
|
0.75
|
|
52
|
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
|
Leuk Res
|
2013
|
0.75
|
|
53
|
Proteasome inhibition in hematologic malignancies: clinical update and practical applications.
|
Oncology (Williston Park)
|
2004
|
0.75
|